Navigation Links
Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering
Date:6/1/2010

SALT LAKE CITY, June 1 /PRNewswire/ -- Glycosan BioSystems announced today that the Company has begun the process for gaining regulatory approval within the European Union for the use of HyStem-Rx as a resorbable scaffold for implanting autologous adipose derived cells in reconstruction and aesthetic plastic surgery procedures.  Upon approval, HyStem-Rx will receive a CE Mark as an implantable medical device.  HyStem-Rx will be indicated for use to correct subcutaneous contour defects arising from traumatic injury, oncologic resections, and other conditions that result in the loss of adipose tissue.

Spokesman for the Company said, "There is increasing recognition that development of successful cell-based therapies will require implanting cells within a matrix to protect them from natural inflammatory processes and to provide a three dimensional scaffold on which cells can attach and proliferate.  HyStem-Rx is a unique biomaterial that was designed as a biocompatible, resorbable mimic of the extra-cellular matrix to be used as a delivery matrix in cell-based therapies.   Pre-clinical studies have shown HyStem-Rx to support the growth of a wide variety of cell types and the proliferation and differentiation of embryonic stem cells as well as neural, hepatic, and adipose derived progenitor cells."

Glycosan BioSystems, Inc. is a privately held Salt Lake City biotechnology company that develops, manufactures, and sells unique biocompatible hydrogels that mimic the extracellular matrix, the complex mixture of macromolecules that holds cells together in tissues and organs.  The Company's products are used in cell culture and stem cell research and have applications as implantable, resorbable scaffolds for tissue engineering, regenerative medicine, and cell-based therapies.  Glycosan is the licensee of the University of Utah Research Foundation for certain intellectual property based on unique chemical cross-linking strategy to prepare hyaluronan based hydrogels from chemically modified hyaluronan and other extracellular matrix constituents.  More information on the Company and its products can be found at www.glycosan.com.


'/>"/>
SOURCE Glycosan BioSystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Online Tutorials for NCBI resources BioSystems and DCODE
2. Microbix Biosystems Re-files Annual Results With OSC
3. Microbix Biosystems Provides a Corporate Update
4. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
5. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
6. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
7. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
8. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
9. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
10. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
11. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... During the course of ... testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the medical ... D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will be ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the ... explore the laboratory testing for DIC in order to illuminate this clinical problem for ... occur in hospitalized patients resulting in a high degree of morbidity and mortality. DIC ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):